Filtered By:
Condition: Thrombosis
Vaccination: Vaccines
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 145 results found since Jan 2013.
Stroke Associated with COVID-19 Vaccines
Development of safe and effective vaccines against coronavirus disease 2019 (COVID-19) remains the cornerstone of controlling this pandemic. However, there are increasing reports of various types of stroke including ischemic stroke, and hemorrhagic stroke, as well ascerebral venous sinus thrombosis (CVST) after COVID-19 vaccination. This paper aims to review reports of stroke associated with COVID-19 vaccines and provide a coherent clinical picture of this condition. Most of such patients are women under 60 years of age and who had received ChAdOx1 nCoV-19 vaccine.
Source: Journal of Stroke and Cerebrovascular Diseases - March 3, 2022 Category: Neurology Authors: Maryam Kakovan, Samaneh Ghorbani Shirkouhi, Mojtaba Zarei, Sasan Andalib Tags: Review Article Source Type: research
Acute Ischemic Stroke Revealing ChAdOx1 nCov-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia: Impact on Recanalization Strategy
We describe a case of a young healthy women suffering from acute ischemic stroke due to large vessel occlusion without cerebral venous thrombosis 8 days after vaccination and its consequences on recanalization strategy.Considering the thrombocytopenia, intravenous thrombolysis was contraindicated. She underwent mechanical thrombectomy with complete recanalization and dramatically improved clinically.
Source: Journal of Stroke and Cerebrovascular Diseases - June 24, 2021 Category: Neurology Authors: Guillaume Costentin, Ozlem Ozkul-Wermester, Aude Triquenot, V éronique Le Cam-Duchez, Nathalie Massy, Ygal Benhamou, Evelyne Massardier Tags: Case Report Source Type: research
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
RARITAN, NJ, May 25, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor (being developed in collaboration with Bristol Myers Squibb), have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients. The Librexia program is unrivaled as the most comprehensive FXIa clinical...
Source: Johnson and Johnson - May 25, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Ischemic Stroke and Vaccine-Induced Immune Thrombotic Thrombocytopenia following COVID-19 Vaccine: A Case Report with Systematic Review of the Literature
Conclusion: Our study points out that, in addition to cerebral venous thrombosis, adenoviral vector-based vaccines also appear to have a cerebral arterial thrombotic risk, and clinicians should be aware that ischemic stroke with LVO, although rare, could represent a clinical presentation of VITT.Cerebrovasc Dis
Source: Cerebrovascular Diseases - May 5, 2022 Category: Neurology Source Type: research
Implications of COVID-19 to Stroke Medicine: An Epidemiological and Pathophysiological Perspective
Curr Vasc Pharmacol. 2022;20(4):333-340. doi: 10.2174/1570161120666220428101337.ABSTRACTThe neurological complications of Coronavirus 2019 (COVID-19) including stroke have been documented in the recent literature. COVID-19-related inflammation is suggested to contribute to both a hypercoagulable state and haemorrhagic transformation, including in younger individuals. COVID-19 is associated with a heightened risk of ischaemic stroke. Haemorrhagic stroke in COVID-19 patients is associated with increased morbidity and mortality. Cerebral venous sinus thrombosis (CVST) accounts for <1% of stroke cases in the general populat...
Source: Current Vascular Pharmacology - November 3, 2022 Category: Drugs & Pharmacology Authors: Alan King Karen M Doyle Source Type: research
